Forge Life Science Partners is a venture capital firm that builds partnerships with outstanding life science entrepreneurs, founders, and operators to create the next generation of groundbreaking therapeutics. It is part of the B-FLEXION Group and its team includes experienced biotech investors, operators, and entrepreneurs with decades of experience in drug discovery and development.
73% of their portfolio is in Biotech & Life Sciences. They made 3 investments in the last 12 months. Their most common stage is series-b (45% of deals). Average disclosed round size is $99.6M (across 10 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
Anand Mehra
Founding Partner
Ben Auspitz
Venture Partner
Heather Berger
Venture Partner
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Khartis Therapeutics | Series B | $50M | Aug 2026 |
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| KKinaset | Series B | $103M | Jan 2026 |
| OOnCusp Therapeutics | Series A | $100M | Jan 2024 |
 OnCusp | Series A | $100M | Jan 2024 |
 IDRx | Series A | — | Aug 2022 |
| IDRx | Series A | $122M | Jan 2022 |
 Escient Pharmaceuticals | Series C | $120M | Jan 2022 |
 Infinimmune | Series A | $75M | — |
 Kinaset Therapeutics | Series B | $103M | — |
| IDRx | Series B | $120M | — |
Top Co-Investors
Last updated: 20 October 2026